Tirzepatide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
A dual GIP/GLP-1 receptor agonist used for weight loss and metabolic health. Human evidence is strong: trials show superior weight loss, glycemic control, and heart failure benefit, with softer data on cardiovascular risk. GI side effects are common, and a boxed warning for thyroid tumors in animal studies rules it out for anyone with a history of medullary thyroid cancer or MEN 2. It is FDA-approved, sold as a regulated pharmaceutical, not research-grade.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Mounjaro and Zepbound (tirzepatide) is a first-in-class dual-action injectable medication that mimics two natural gut hormones — GIP and GLP-1 — that your body releases after eating to signal fullness and regulate blood sugar. It is FDA-approved as Mounjaro for type 2 diabetes, Zepbound for chronic weight management, and also for obstructive sleep apnea related to obesity. Dosed once weekly, it represents one of the most effective weight loss medications ever developed.
How it works in the body
A dual GIP and GLP-1 receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 are incretin hormones released after eating. By activating both receptors simultaneously, tirzepatide produces stronger insulin secretion, greater appetite suppression, and more weight loss than either pathway alone.
Research overview
Tirzepatide works by simultaneously activating both the GIP and GLP-1 receptors, triggering multiple mechanisms: boosting insulin release when blood sugar is high, suppressing the hormone glucagon, slowing stomach emptying so you feel full longer, and reducing appetite through direct effects on brain hunger centers. Its built-in fatty acid chain binds to albumin in the blood, allowing it to last a full week per dose. Clinical trials showed tirzepatide improves insulin sensitivity beyond what single-target GLP-1 drugs like semaglutide achieve. In the SURMOUNT trials for weight management, participants lost up to 22.5% of body weight on the highest dose. The dual mechanism is thought to explain its superior efficacy compared to GLP-1-only drugs, and SURMOUNT-5 has published head-to-head weight-loss results.
Who researches Tirzepatide?
Commonly researched by
People researching weight management options
Studied for effects on body composition, appetite regulation, or metabolic rate.
People exploring sleep quality improvement
Researched for effects on sleep architecture, circadian rhythm, or sleep quality.
People researching cardiovascular health
Studied for effects on heart function, blood pressure, or vascular health.
People researching blood sugar regulation
Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.
Important considerations for
Those with Personal/family history of medullary thyroid carcinoma
AbsoluteSame thyroid C-cell tumor risk as other incretin-based therapies. Contraindicated in MTC/MEN2.
Those with History of pancreatitis
HighMonitor closely. Discontinue if pancreatitis suspected.
Those with Severe gastroparesis
HighDual GIP/GLP-1 action significantly slows gastric emptying.
Those who are pregnant or breastfeeding
AbsoluteDiscontinue at least 2 months before planned conception.
Safety & interactions
Do not use if
Personal/family history of medullary thyroid carcinoma
AbsoluteSame thyroid C-cell tumor risk as other incretin-based therapies. Contraindicated in MTC/MEN2.
History of pancreatitis
HighMonitor closely. Discontinue if pancreatitis suspected.
Severe gastroparesis
HighDual GIP/GLP-1 action significantly slows gastric emptying.
General cautions
Pregnancy
AbsoluteDo not use during pregnancy. MHRA guidance recommends stopping tirzepatide at least 1 month before a planned pregnancy.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
GI side effects: nausea (13-24%), diarrhea (13-21%), vomiting (6-14%)
HighFDA Mounjaro/Zepbound prescribing information (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide); PMID 39555826 (SUMMIT)
Boxed warning: thyroid C-cell tumors in animal studies
ModerateFDA Mounjaro/Zepbound prescribing information, Boxed Warning (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
Pancreatitis risk (rare)
LowFDA Mounjaro/Zepbound prescribing information, Warnings and Precautions (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
Gallbladder disease
ModerateFDA Zepbound prescribing information, Warnings and Precautions (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
Potential for hypoglycemia when combined with insulin or sulfonylureas
ModerateFDA Mounjaro prescribing information, Warnings and Precautions / Drug Interactions (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
Contraindicated: personal/family history of medullary thyroid carcinoma or MEN 2
HighFDA Mounjaro/Zepbound prescribing information, Contraindications (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
Interaction summary(8)
Rated by direction with this peptide
Insulin and sulfonylureas (e.g. glimepiride, glipizide)
CautionHighAdding tirzepatide to insulin or a sulfonylurea substantially raises the rate of clinically significant hypoglycemia; the label advises considering a dose reduction of the insulin or secretagogue when starting.
FDA Mounjaro prescribing information, Warnings and Precautions 5.4 / Drug Interactions (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
Oral hormonal contraceptives
CautionHighTirzepatide delays gastric emptying and reduces oral contraceptive exposure, and the label directs patients to switch to a non-oral method or add a barrier method for 4 weeks after initiation and after each dose escalation — a real, PK-demonstrated interaction with pregnancy-risk consequences.
FDA Mounjaro/Zepbound prescribing information, Drug Interactions 7.1 (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
Other GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and DPP-4 inhibitors
CautionModerateConcurrent use is redundant on the same incretin axis with no demonstrated added benefit and additive GI toxicity; tirzepatide has not been studied with other GLP-1 RAs and co-prescription is not recommended.
FDA Mounjaro prescribing information, Limitations of Use / Clinical Pharmacology (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
Anesthesia and procedural sedation (elective surgery, endoscopy)
CautionModerateDelayed gastric emptying can leave retained gastric contents despite standard fasting, raising pulmonary aspiration risk; anesthesiology consensus guidance recommends holding weekly GLP-1/GIP agonists before elective procedures and treating patients as full-stomach if symptomatic.
American Society of Anesthesiologists consensus-based guidance on preoperative management of GLP-1 receptor agonists (2023); FDA label Warnings and Precautions (pulmonary aspiration)
Narrow-therapeutic-index oral drugs (warfarin, levothyroxine, digoxin, antiepileptics)
CautionLowSlowed gastric emptying can alter the rate and, less predictably, extent of oral absorption, so the label advises monitoring where small exposure changes matter clinically — mechanism-based rather than demonstrated for most individual agents.
FDA Mounjaro prescribing information, Drug Interactions 7.2 (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
Diuretics, ACE inhibitors/ARBs and NSAIDs
CautionModerateDuring tirzepatide-related vomiting or diarrhea, volume depletion on top of these agents can precipitate acute kidney injury or worsen existing renal impairment — an explicitly labeled warning, with reported post-marketing AKI cases.
FDA Mounjaro prescribing information, Warnings and Precautions (acute kidney injury) (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
SGLT2 inhibitors (empagliflozin, dapagliflozin)
SynergisticLowComplementary mechanisms give additive HbA1c, weight and cardiorenal benefit and the combination is widely used, but both promote volume loss, so hydration and renal function warrant attention during GI illness.
FDA Mounjaro prescribing information (concomitant use in SURPASS program); ADA Standards of Care
Metformin
NeutralLowNo clinically relevant pharmacokinetic interaction; metformin was background therapy in most SURPASS trials, though overlapping GI effects can compound nausea and diarrhea during dose escalation.
FDA Mounjaro prescribing information, Clinical Pharmacology 12.3 (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
Known risks(6)
GI side effects: nausea (13-24%), diarrhea (13-21%), vomiting (6-14%)
Boxed warning: thyroid C-cell tumors in animal studies
Pancreatitis risk (rare)
Gallbladder disease
Potential for hypoglycemia when combined with insulin or sulfonylureas
Contraindicated: personal/family history of medullary thyroid carcinoma or MEN 2
Drug interactions(4)
Semaglutide
Both act on GLP-1 receptors. Combining increases GI side effects and hypoglycemia risk.
Insulin
Increased hypoglycemia risk. Reduce insulin dose when starting tirzepatide.
Sulfonylureas
Hypoglycemia risk. Consider dose reduction.
Oral contraceptives
Slowed gastric emptying may reduce absorption. Use a barrier method for 4 weeks after starting treatment and after each increase.
Research & benefits
Evidence base
- Evidence Level
- Level 1 — Strong
- Total Studies
- 600
- Human Participants
- 35000
600+ PubMed studies. 35,000+ participants across SURPASS (T2DM), SURMOUNT (obesity), SUMMIT (HFpEF), SYNERGY-NASH, SURMOUNT-OSA programs. SURPASS-CVOT alone had 13,000+ patients over 4+ years.
Researched for(8)
Rated by confidence in the evidence
Superior weight loss
HighMultiple large RCTs showed 15-21% weight loss, exceeding semaglutide in a head-to-head trial.
PMID 35658024 (SURMOUNT-1, NEJM 2022); PMID 37385275 (SURMOUNT-2, Lancet 2023); PMID 34170647 (SURPASS-2, NEJM 2021)
Glycemic control
HighMultiple phase 3 trials showed HbA1c reductions of 2-2.6 points, beating semaglutide and insulin.
PMID 34170647 (SURPASS-2, NEJM 2021); FDA Mounjaro prescribing information (https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tirzepatide)
T2D prevention
HighSingle large trial found a 93% reduction in diabetes progression among adults with prediabetes.
PMID 39536238 (Jastreboff et al., NEJM 2025 — SURMOUNT-1 3-year prediabetes results)
Heart failure (HFpEF)
HighDedicated RCT in obesity-related HFpEF found 38% fewer cardiovascular deaths or worsening heart failure events.
PMID 39555826 (Packer et al., NEJM 2025 — SUMMIT)
CV risk reduction
MediumLarge outcomes trial showed noninferiority to another GLP-1 drug, not superiority, for cardiovascular events.
PMID 41406444 (Nicholls et al., NEJM 2025 — SURPASS-CVOT); PMID 39555826 (SUMMIT)
MASH/NASH resolution
MediumOne 52-week trial found MASH resolution in up to 62% versus 10% with placebo.
PMID 38856224 (Loomba et al., NEJM 2024 — SYNERGY-NASH)
Sleep apnea
HighTwo large RCTs cut AHI by 25-29 events per hour in obesity-related sleep apnea, FDA-approved.
PMID 38912654 (Malhotra et al., NEJM 2024 — SURMOUNT-OSA)
Cardiometabolic
HighConsistent improvements in blood pressure, lipids, and inflammation seen as secondary trial endpoints.
PMID 35658024 (SURMOUNT-1); PMID 38912654 (SURMOUNT-OSA); PMID 34170647 (SURPASS-2)
Benefits(8)
Superior weight loss
Glycemic control
T2D prevention
Heart failure (HFpEF)
CV risk reduction
MASH/NASH resolution
Sleep apnea
Cardiometabolic
Key studies(5)
Jastreboff AM et al.
NEJM
2022
22.5% weight loss at 15mg/72wk. 63% achieved ≥20% loss.
Frias JP et al.
NEJM
2021
All doses superior to semaglutide 1mg for HbA1c and weight
Aronne LJ et al.
NEJM
2025
20.2% vs 13.7% weight loss head-to-head
Packer M et al.
NEJM
2025
38% reduction CV death/worsening HF (HR 0.62)
Loomba R et al.
NEJM
2024
62% MASH resolution at 15mg, liver fat -57%
What research suggests over time
Weeks 2-4
SURMOUNT-1 (NEJM 2022)Appetite suppression begins; ~2-3% body weight loss after the first month of titration.
Months 2-3
SURMOUNT-1 / SURPASS-2~7-10% weight loss as treatment escalates; A1c reductions of 1.5-2.0% in T2DM.
Long-term
Phase 3 RCTMean 22.5% weight loss at 72 weeks (highest-dose arm). SURMOUNT-4 showed 82% of users regained >25% within 1 year of stopping.
Prescribing labels
FDA-Approved Labels
This page does not list doses. Each product below has an FDA label with its prescribing information.
- Protocol
- Mounjaro (tirzepatide)
- Notes
- Dosing is set by your prescriber and the FDA label.
- Source
- FDA label on DailyMed
- Protocol
- Zepbound (tirzepatide)
- Notes
- Dosing is set by your prescriber and the FDA label.
- Source
- FDA label on DailyMed
Monitoring & labs
Baseline before starting, then per marker schedule during protocol.
Baseline labs(7)
Complete Blood Count (CBC)
Optimal All markers within mid-rangeEstablishes baseline for detecting hematological changes.
Lab normal Standard reference ranges
Comprehensive Metabolic Panel (CMP)
Optimal Liver enzymes <25, glucose 75–90, eGFR >90Liver and kidney function baseline.
Lab normal Standard reference ranges
Fasting glucose + HbA1c
Optimal 75–90 mg/dLBaseline metabolic markers — critical for tracking glucose regulation changes.
Lab normal 65–99 mg/dL
Lipid panel
Optimal ApoB <80, TG <80, HDL >55Cholesterol and triglyceride baseline for tracking cardiovascular metabolic effects.
Lab normal TC <200, LDL <100, HDL >40, TG <150
Thyroid panel (TSH, free T3/T4)
Optimal TSH 1.0–2.0; Free T3 upper third of rangeThyroid function can be affected by metabolic peptides.
Lab normal TSH 0.4–4.5
Amylase + Lipase
Optimal Both within mid-rangeBaseline pancreatic markers — this peptide carries a documented pancreatitis risk.
Lab normal Standard ranges
Calcitonin
Optimal Under 5 pg/mLBaseline thyroid C-cell marker — this peptide carries a thyroid tumor risk warning.
Lab normal Under 10 pg/mL (men)
Ongoing tracking(5)
Fasting glucose + HbA1c
Every 4-8 weeksOptimal 75–90 mg/dLTrack glucose regulation changes during protocol.
Lab normal 65–99 mg/dL
Lipid panel
Every 8-12 weeksOptimal ApoB <80, TG <80, HDL >55Monitor cholesterol and triglyceride response.
Lab normal TC <200, LDL <100, HDL >40, TG <150
Liver enzymes (ALT/AST)
Every 8 weeksOptimal ALT & AST under 25 U/LHepatic function monitoring during metabolic modulation.
Lab normal ALT 7–56, AST 10–40 U/L
Amylase + Lipase
Every 8-12 weeksOptimal Both within mid-rangePancreatic enzyme monitoring — pancreatitis risk.
Lab normal Standard ranges
Calcitonin
Every 12 weeksOptimal Under 5 pg/mLThyroid C-cell monitoring — MTC risk.
Lab normal Under 10 pg/mL (men)
Retest schedule(6)
Baseline
critical
Before starting
Full baseline + thyroid panel, lipase, amylase, HbA1c, lipid panel.
Early follow-up
critical
Week 4
Recheck lipase, amylase, glucose. Most early-protocol concerns surface here.
Second check
critical
Week 8
Recheck metabolic markers and GI tolerance.
Mid-protocol
critical
Week 12
Comprehensive retest. Track HbA1c, weight, lipids, thyroid.
Ongoing
standard
Every 12 weeks
Sustained metabolic monitoring during chronic use.
Post-protocol
standard
4-6 weeks after stopping
Track for weight regain and metabolic rebound.
When to stop and reassess(7)
ALT or AST
stopAbove 2× upper limit of normal (>~80 U/L)
Stop protocol and consult a provider — possible drug-induced liver injury.
eGFR
stopDrop of >15 mL/min/1.73m² from baseline, or below 60
Stop protocol and consult a provider — possible kidney function decline.
Symptoms
stopNew severe symptoms correlating with lab changes
Stop protocol and seek medical evaluation immediately.
Lipase or amylase
stopAbove 3× upper limit of normal
Stop protocol and seek urgent medical evaluation — possible pancreatitis.
Calcitonin
consultAbove 10 pg/mL or rising trend
Consult an endocrinologist — possible thyroid C-cell stimulation.
Heart rate
consultSustained >100 bpm or new palpitations
Consult a provider — GLP-1 agonists can affect cardiac rhythm.
Lipase
stopAbove 3× upper limit of normal
Stop protocol and seek urgent medical evaluation — pancreatitis risk documented.
Lab monitoring helps track your body's response to Tirzepatide. Any unexplained changes should prompt discussion with your prescribing provider.
Regulation & availability
Why researchers look at it
SURMOUNT trial participants lost up to 22.5% of body weight — surpassing semaglutide in head-to-head comparisons — making it the most effective weight loss medication in clinical history. Across 35,000+ participants (SURPASS, SURMOUNT, SUMMIT), benefits extend well beyond weight: reduced heart failure hospitalizations, improved liver fat, and resolution of sleep apnea. SURPASS-CVOT has reported cardiovascular noninferiority to dulaglutide; superiority for its primary cardiovascular endpoint was not established.
- Estimated cost
- Self-pay $299-699/mo for Zepbound by dose (LillyDirect, checked 21 Oct 2026); $90-399/mo compounded through telehealth; some providers add a membership fee
- FDA status
- FDA-approved: Mounjaro (T2DM May 2022), Zepbound (obesity November 2023, OSA December 2024). Zepbound KwikPen launched February 2026. Shortage-related compounding enforcement discretion ended in 2025; enforcement continues. According to Lilly, Zepbound was the most prescribed weight-management drug in the U.S. in 2025.
- WADA status
- Not explicitly banned. Under monitoring similar to other incretin therapies.
- Prescribability
- FDA-approved Rx. Mounjaro (T2DM, May 2022), Zepbound (obesity Nov 2023, OSA Dec 2024). Compounding largely ended after FDA's shortage-related enforcement discretion ended in early 2025.
- Availability
- Rx only. Mounjaro and Zepbound are available at pharmacies, with LillyDirect self-pay options. Zepbound KwikPen was approved January 20, 2026 and launched February 23. Shortage-related compounding discretion ended in March 2025. Medicare GLP-1 Bridge access to Zepbound KwikPen began July 1, 2026 for eligible beneficiaries.
International status
EU
EMA-approved (Mounjaro)
UK
MHRA-approved
US
FDA-approved (Mounjaro, Zepbound)
Japan
PMDA-approved
Canada
Health Canada-approved
Australia
TGA-approved
Regulatory timeline(5)
- 2022-05Mounjaro FDA approvalT2DM indication
- 2023-11Zepbound FDA approvalWeight management indication
- 2024-10Shortage resolvedFDA ended tirzepatide shortage. Compounding enforcement began.
- 2024-12Zepbound OSA approvalModerate-to-severe obstructive sleep apnea
- 2026-01-20KwikPen approvedMulti-dose pen for Zepbound. Self-pay from $299/mo via LillyDirect.
Sources & FAQs
Research sources(5)
Frequently asked questions(4)
How does it differ from semaglutide?
Dual GIP/GLP-1 vs GLP-1 only. Greater weight loss (20.2% vs 13.7% head-to-head) and superior HbA1c reduction.
Common side effects?
GI: nausea 13-24%, diarrhea 13-21%, vomiting 6-14%. Mild-moderate, diminish over time. Discontinuation 4-10%.
Compounded tirzepatide in 2026?
Largely unavailable. Shortage resolved Oct 2024. FDA enforcement active. Brand Mounjaro/Zepbound or LillyDirect self-pay vials.
CV benefits beyond weight loss?
Yes: 38% HF reduction (SUMMIT), 16% all-cause mortality reduction (SURPASS-CVOT), significant BP and triglyceride improvements.